Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 study of AZD2014 in Japanese patients with advanced solid malignancies
jRCT2080222811Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Apr 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of vistusertib in Non-hematologic malignancy (2 arms), sponsored by AstraZeneca. Primary endpoints: Safety and tolerability of AZD2014 (monotherapy and with paclitaxel) and Pharmacokinetics of AZD2014. Started Apr 2015; status: completed.
02
Drugs
vistusertib
03
Conditions
Non-hematologic malignancy
Beyond the preview
Go deeper on jRCT2080222811.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222811.